TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04382885
Drug: Cariprazine
Normalized name: Cariprazine
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Solution
Study: NCT02531724
Drug: Levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03565536
Drug: Nexavar
Normalized name: Nexavar
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: for Unresectable tumors ,After the patient had diagnosed as anaplastic thyroid cancer, Nexavar 400mg Bid was used for neoadjuvant treatment. At 1 month and 2 months after treatment, it was assessed whether surgery could be performed.
Study: NCT00096980
Drug: Raptiva (efalizumab)
Normalized name: Raptiva
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00756418
Drug: montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: montelukast 5 mg QD 4-weeks.
Study: NCT02053636
Drug: lucitanib
Normalized name: Lucitanib
DrugBank: Lucitanib (DB11845)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00481923
Drug: rimonabant (SR141716)
Normalized name: rimonabant
DrugBank: Rimonabant (DB06155)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT00003811
Drug: amifostine trihydrate
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003811
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003811
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00018967
Drug: glucarpidase
Normalized name: Glucarpidase
DrugBank: Glucarpidase (DB08898)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04702841
Drug: Chimeric antigen receptor modified γδ T cells
Normalized name: Autologous T cells transduced with retroviral vector encoding an anti-CD-19 CD28/CD3-zeta chimeric antigen receptor
DrugBank: Axicabtagene ciloleucel (DB13915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage: the total dosage of reinfusion is 0.2-5 × 10\^6 / kg, which is determined according to the body weight of the subject and the effective content of cell preparation.
Study: NCT00820469
Drug: Rituximab 375
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: rituximab 375 mg/m2 IV weekly, during 4 weeks
Study: NCT00820469
Drug: rituximab 1000
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: rituximab 1000 mg IV, two infusions on day 1 and day 15
Study: NCT04709744
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impact of serum vit D level in SLE patients with COVID-19 disease on severity of infection, duration of COVID-19 disease course, fatigue development as a complication for both SLE and COVID-19 and assess impact of prior chloroquine on COVID-19 disease outcomes
Study: NCT03619850
Drug: Ferumoxytol
Normalized name: Ferumoxytol
DrugBank: Ferumoxytol (DB06215)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution.
Study: NCT03619850
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL).
Study: NCT00404638
Drug: Desmopresin
Normalized name: Desmopresina
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02743013
Drug: CHF 5993 100/6/12,5 pMDI with Valved Holding Chamber
DrugBank: Amber (DB14326)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04184297
Drug: Tiotropium and Olodaterol (Tio+Olo)
Normalized name: olodaterol / tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug
Study: NCT00834262
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT00834262
Drug: biphasic insulin aspart 50
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT00834262
Drug: biphasic insulin aspart 70
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT03967054
Drug: Ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin (6 mg tablet) given monthly from July-October each rainy season as a 3-day course of approximately 300 mcg/kg/day as estimated by height bands.
Study: NCT00977626
Drug: Part 1 - AZD2423 or Placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: AZD2423 Oral Solution, multiple dosing during 10-14 days or Placebo Oral Solution, multiple dosing during 10-14 days
Study: NCT00977626
Drug: Part 2 - AZD2423
Normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2423 Oral solution, multiple dosing
Study: NCT00977626
Drug: Part 3 - AZD2423
Normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2423 Oral solution, single dosing or AZD2423 Oral solution, single dosing - With Food or AZD2423 Oral solution, single dosing - Fasting Condition.
Study: NCT03871699
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration of Ferric Carboxymaltose intravenously, one dose only.
Study: NCT01815827
Drug: inclacumab
Normalized name: Inclacumab
DrugBank: Inclacumab (DB12246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single intravenous doses
Study: NCT01171313
Drug: XP21279 and carbidopa (experimental)
Normalized name: Carbidopa and Levodopa Tablets
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed XP21279 and Carbidopa
Study: NCT01171313
Drug: Sinemet (comparator)
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed Sinemet.
Study: NCT00385801
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00922311
Drug: Aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titrate from 150 mg daily to 300 mg daily
Study: NCT01171313
Drug: Placebo for XP21279 and carbidopa
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for XP21279 and carbidopa
Study: NCT00208767
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan was titrated to a target dose of 320 mg orally daily
Study: NCT02163915
Drug: TAK-137
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-137 tablets
Study: NCT03165149
Drug: group (A)
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
DrugBank: 2-Bromoacetyl Group (DB02198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive 1mg / kg of Ketamine diluted by 20 ml saline (0.9 % ) and irrigated onto surgical field after hemostats and before skin closure.
Study: NCT03165149
Drug: group (B)
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
DrugBank: 2-Bromoacetyl Group (DB02198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive 2 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) and irrigated onto surgical field after hemostasis and before skin closure.
Study: NCT03165149
Drug: group (c)
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
DrugBank: 2-Bromoacetyl Group (DB02198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive 3 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) and irrigated onto surgical field after hemostasis and before skin closure.
Study: NCT00878748
Drug: Effexor XR
Normalized name: Effexor XR
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01393912
Drug: Crenolanib
Normalized name: Crenolanib
DrugBank: Crenolanib (DB11832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crenolanib orally administered as whole or crushed tablets once per day with concurrent Radiation Therapy. Crenolanib will continue at the same dose level post Radiation Therapy
Study: NCT00290849
Drug: Bivalirudin
Normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03860220
Drug: NEWSTATIN TS
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Wash out/run in period with Amlodipine 5mg for 6 weeks and then treatment with triple therapy (Newstatin TS 40/5/10mg) ; 1 tab qd for 8 weeks
Study: NCT03860220
Drug: CADUET
Normalized name: Caduet
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Wash out/run in period with Amlodipine 5mg for 6 weeks and then treatment with dual therapy (Caduet 5/10mg) ; 1 tab qd for 8 weeks
Study: NCT03256136
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy
Study: NCT03256136
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: will allow the body's immune system to work against tumor cells
Study: NCT03256136
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Chemo therapy
Study: NCT03256136
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: will allow the body's immune system to work against tumor cells
Study: NCT00907218
Drug: Varenicline (Chantix)
Normalized name: varenicline Oral Tablet [Chantix]
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upon completion of screening procedures and meeting eligibility criteria, subjects will begin taking varenicline daily until Week 6 of the study. At Week 6 they will discontinue varenicline and return one week later for their final study visit to assess return of ADHD symptomatology. Subjects will start on 0.5 mg of varenicline per day for the first week of treatment. The dose will be increased to 0.5 mg twice a day at the end of week 1 visit, and then increased to 1 mg twice a day at the end of week 2 visit, to remain at this dose until the week 6 visit. At week 6, all subjects will be openly discontinued from varenicline, to return to the office the following week for re-assessment one week off the medication. If significant adverse effects (AE) occur, the daily dose may be reduced by 0.5 to 1 mg. At subsequent visits, a higher dose may be resumed if tolerated. Maximum dose will be 2 mg daily.
Study: NCT02725736
Drug: Atosiban
Normalized name: atosiban
DrugBank: Atosiban (DB09059)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: After random allocation to a treatment group, women will receive Atosiban as follows:~Atosiban was given as a single loading intravenous dose, 6.75 mg in 0.9% sodium chloride solution, followed by an intravenous infusion of 300 micrograms/min in 0.9% sodium chloride solution for the first 3 hours and then 100 micrograms/min for another 45 hours. The choice of the dose regimen for Atosiban was consistent with the recommendations of the product labeling.
Study: NCT02725736
Drug: Nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After random allocation to a treatment group, women will receive Nifedipine as follows:~Nifedipine was given as a loading dose of 20 mg orally followed by another two doses of 20 mg, 20-30 minutes apart as needed. Maintenance was started after 6 hours with 20-40 mg four times a day for a total of 48 hours.
Study: NCT03779698
Drug: Formocresol
Normalized name: Formocresol
DrugBank: Cresol (DB11143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In control group, a sterile cotton pellet moistened with 1:5 concentration formocresol then blotted to remove excess was placed for 5 minutes on the pulp stumps and then the pulps were covered with zinc oxide-eugenol (IRM; Dentsply, Milford, DE) dressing. Follow-up was done for all children clinically at 3, 6 and 12 months and radiographically at 6 and 12 months.
Study: NCT00696618
Drug: tap water enema
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hypo-osmolar preparation
Study: NCT00696618
Drug: Normosol-R enema
Normalized name: Normosol-R
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iso-osmolar preparation
Study: NCT02614118
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg oral Ketorolac tromethamine 45 minutes before root canal treatment
Study: NCT04119674
Drug: Drug is Anlotinib.
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib 8 mg/day (Chia-tai Tianqing Pharmaceutical Co., Ltd.) was given orally on days 1 to 14 per 3-week cycle for 2 cycles during concomitant therapy and maximally 8 cycles during adjuvant chemotherapy. One week after discontinuation of adjuvant chemotherapy, anlotinib 8 mg/day was given for maintenance .
Study: NCT04119674
Drug: Drug is Temozolomide Capsule.
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide 75 mg/m2/day was taken for maximally 49 days during concurrent chemoradiotherapy. Beginning 4 weeks after completion of concurrent chemoradiotherapy, patients received adjuvant temozolomide for 5 days every 28 days, first cycle 150 mg/m2/day and subsequent cycles 200 mg/m2/day for maximally 6 cycles .
Study: NCT01396291
Drug: asenapine
Normalized name: Asenapine
DrugBank: Asenapine (DB06216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: asenapine, sublingual tablets, 5 to 10 mg twice per day (BID)
Study: NCT00722475
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusions, 25-35 g each time, 4th to 15th gestational week
Study: NCT00722475
Drug: Human albumin
Normalized name: Human albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated infusions of Human Albumin 5%, 250-350 ml between 4th and 15th gestational week
Study: NCT00322387
Drug: G-CSF and plerixafor
Normalized name: G-CSF
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: G-CSF and plerixafor were administered as described in the treatment arms.
Study: NCT02224274
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02224274
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03395353
Drug: Duloxetine Hydrochloride
Normalized name: Duloxetine Hydrochloride
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02026219
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 600mg loading
Study: NCT02026219
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 180mg loading
Study: NCT02511639
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus is formulated as tablets of 10 mg strength for oral administration.
Study: NCT02225093
Drug: Dextromethorphan
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral /.L
Study: NCT02225093
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral
Study: NCT02225093
Drug: Enzalutamide Placebo to Match (PTM)
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral
Study: NCT00156117
Drug: asenapine
Normalized name: Asenapine
DrugBank: Asenapine (DB06216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg BID or 10mg BID
Study: NCT00156117
Drug: olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: olanzapine 15 mg QD
Study: NCT00111020
Drug: Sorafenib (Nexavar, BAY43-9006)
Normalized name: sorafenib 200 MG [Nexavar]
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multi kinase inhibitor: 400 mg of Sorafenib, orally, twice a day, on a continuous basis as a single agent for the treatment of advanced RCC
Study: NCT00329732
Drug: 0.5% bupivicaine and 2% lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The injectors will infiltrate an area of 2cm along the occipital ridge centering around the occipital artery or around the site 1/3 from the mastoid to the inion. If the subject has a bilateral headache or the headache is known to switch sides then the block will be performed bilaterally. If the headache is strictly unilateral, the block will be performed only on the side of the headache
Study: NCT01477619
Drug: Tasimelteon
Normalized name: Tasimelteon
DrugBank: Tasimelteon (DB09071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg single dose on Day 1
Study: NCT00774969
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole 10% ointment three times a day 7 days
Study: NCT03410524
Drug: Simethicone Solution
Normalized name: Simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of Simethicone in 3 mL of Simethicone Solution Formulation
Study: NCT02433717
Drug: Paliperidone ER
Normalized name: Paliperidone ER
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fixed dose (9 mg/day) of paliperidone ER will be given in the first two weeks of trial (from day 1 to day 14). Since the third week (day 15), the dosage can be adjusted in the range of 6 to 12 mg per day.
Study: NCT02832037
Drug: BI 425809 dose 1
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02832037
Drug: BI 425809 dose 2
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02832037
Drug: BI 425809 dose 3
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02832037
Drug: BI 425809 dose 4
Normalized name: bis(4-aminophenyl)sulfone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03410524
Drug: Water
Normalized name: Water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL of water as placebo added to the bowel preparation
Study: NCT02745041
Drug: Fibrinogen Concentrate
Normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen Replacement using Fibrinogen Concentrate as per ROTEM guided treatment algorithm \[FIBTEM ≤ A5 10mm\]~FIBTEM A5 0mm (Flat Line) = 6g FC FIBTEM A5 1 - 4mm = 5g FC FIBTEM A5 5 - 6mm = 4g FC FIBTEM A5 7 - 8mm = 3g FC FIBTEM A5 9 - 10mm = 2g FC
Study: NCT01188811
Drug: lipoic acid
Normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg taken by mouth daily starting on day one of the study and ending on the last day of study participation.
Study: NCT00858624
Drug: ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of low dose intravenous ketamine. Dose: 0.075mg/kg over 10 minutes followed by 0.005mg/kg/min over 20 minutes. Given as single infusion.
Study: NCT02518763
Drug: Vitamin D3, 100 000 IU weekly, 4 times
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00623506
Drug: Pregnenolone
Normalized name: Pregnenolone
DrugBank: Pregnenolone (DB02789)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for two weeks (during placebo lead-in), then:~Pregnenolone 100 mg in divided doses (50 mg, PO, BID) Pregnenolone 300 mg in divided doses (150 mg, PO, BID) Pregnenolone 500 mg in divided doses (250 mg, PO, BID)
Study: NCT02379546
Drug: Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desflurane will be used to maintain the anesthesia and the dose of desflurane will be adjusted according to the Bispectral İndex Monitoring
Study: NCT02052648
Drug: Indoximod
Normalized name: Indoximod
DrugBank: Indoximod (DB12827)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02052648
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02052648
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04661046
Drug: Traditional Chinese Medicine
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
DrugBank: Borneol (DB11288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine prescription
Study: NCT00034892
Drug: Olanzapine, risperidone
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03646123
Drug: brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.2 mg/kg by IV infusion
Study: NCT03646123
Drug: vinblastine
Normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 mg/m\^2 by IV infusion
Study: NCT03646123
Drug: dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 375 mg/m\^2 by IV infusion
Study: NCT03646123
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Granulocyte colony stimulating factor (G-CSF) primary prophylaxis administered 24-36 hours after each dose of A+AVD